MedTrace Logo

Contrast (Sonazoid)-Enhanced US as a Screening Tool for Hepatocellular Carcinoma in Cirrhosis: An Exploratory Cross-sectional Study

NCT02188901 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 523

Last updated 2018-04-26

No results posted yet for this study

Summary

B-mode ultrasonography (B-US), a standard method of surveillance of hepatocellular carcinoma (HCC), has a fair sensitivity of 63% in detecting early stage HCC. Sonazoid, a contrast agent for ultrasonography, has reported to have superior sensitivity in detecting focal liver lesion since it has ability of Kupffer phase imaging as well as vascular phase imaging. So our aim is to compare the detection rate of early stage HCC and false referral rate of HCC between B-mode US and Sonazoid-enhanced ultrasonography (S-US) within the same prospective data group. Our hypothesis is that S-US has superior detection rate of early stage HCC (5%) than that of B-mode US (3%).

Conditions

  • Hepatocellular Carcinoma (HCC)

Interventions

OTHER

Sonazoid-enhanced ultrasonography

Sonazoid (perflubutane) \[GE healthcare\]

Sponsors & Collaborators

  • GE Healthcare

    collaborator INDUSTRY

  • Yonsei University

    lead OTHER

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-15
Primary Completion
2016-08-03
Completion
2016-08-03

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02188901 on ClinicalTrials.gov